Cargando…
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
Mutations in the hotspot ligand-binding domain of the estrogen receptor (ER) gene ESR1 have recently been recognized as mechanisms of endocrine resistance in endocrine receptor-positive metastatic breast cancer (MBC). Accumulating data suggest these mutations develop under the selective pressure of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966519/ https://www.ncbi.nlm.nih.gov/pubmed/31795152 http://dx.doi.org/10.3390/cancers11121894 |
_version_ | 1783488752307404800 |
---|---|
author | De Santo, Irene McCartney, Amelia Migliaccio, Ilenia Di Leo, Angelo Malorni, Luca |
author_facet | De Santo, Irene McCartney, Amelia Migliaccio, Ilenia Di Leo, Angelo Malorni, Luca |
author_sort | De Santo, Irene |
collection | PubMed |
description | Mutations in the hotspot ligand-binding domain of the estrogen receptor (ER) gene ESR1 have recently been recognized as mechanisms of endocrine resistance in endocrine receptor-positive metastatic breast cancer (MBC). Accumulating data suggest these mutations develop under the selective pressure of endocrine treatments, and are infrequent in untreated ER-positive breast cancers. In vitro studies show that these mutations confer ligand-independent activity, resistance to estrogen deprivation, and relative resistance to tamoxifen and fulvestrant. Post-hoc retrospective and prospective analyses of ESR1 mutations in patients with MBC have consistently found that these mutations are markers of poor prognosis and predict resistance to aromatase inhibitors (AIs). These results warrant further investigation and prospective validation in dedicated studies. Moreover, studies are ongoing to clarify the activity of novel drugs in the context of metastatic endocrine resistant luminal breast cancer harboring ESR1 mutations. In this review, we summarize the pre-clinical and clinical findings defining the characteristics of ESR1 mutant breast cancer, and highlight the potential clinical developments in this field. |
format | Online Article Text |
id | pubmed-6966519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69665192020-01-27 The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy De Santo, Irene McCartney, Amelia Migliaccio, Ilenia Di Leo, Angelo Malorni, Luca Cancers (Basel) Review Mutations in the hotspot ligand-binding domain of the estrogen receptor (ER) gene ESR1 have recently been recognized as mechanisms of endocrine resistance in endocrine receptor-positive metastatic breast cancer (MBC). Accumulating data suggest these mutations develop under the selective pressure of endocrine treatments, and are infrequent in untreated ER-positive breast cancers. In vitro studies show that these mutations confer ligand-independent activity, resistance to estrogen deprivation, and relative resistance to tamoxifen and fulvestrant. Post-hoc retrospective and prospective analyses of ESR1 mutations in patients with MBC have consistently found that these mutations are markers of poor prognosis and predict resistance to aromatase inhibitors (AIs). These results warrant further investigation and prospective validation in dedicated studies. Moreover, studies are ongoing to clarify the activity of novel drugs in the context of metastatic endocrine resistant luminal breast cancer harboring ESR1 mutations. In this review, we summarize the pre-clinical and clinical findings defining the characteristics of ESR1 mutant breast cancer, and highlight the potential clinical developments in this field. MDPI 2019-11-28 /pmc/articles/PMC6966519/ /pubmed/31795152 http://dx.doi.org/10.3390/cancers11121894 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review De Santo, Irene McCartney, Amelia Migliaccio, Ilenia Di Leo, Angelo Malorni, Luca The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy |
title | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy |
title_full | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy |
title_fullStr | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy |
title_full_unstemmed | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy |
title_short | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy |
title_sort | emerging role of esr1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966519/ https://www.ncbi.nlm.nih.gov/pubmed/31795152 http://dx.doi.org/10.3390/cancers11121894 |
work_keys_str_mv | AT desantoirene theemergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT mccartneyamelia theemergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT migliaccioilenia theemergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT dileoangelo theemergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT malorniluca theemergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT desantoirene emergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT mccartneyamelia emergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT migliaccioilenia emergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT dileoangelo emergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy AT malorniluca emergingroleofesr1mutationsinluminalbreastcancerasaprognosticandpredictivebiomarkerofresponsetoendocrinetherapy |